ME Therapeutics Secures NRC IRAP Funding to Advance mRNA Cancer Therapies

VANCOUVER, British Columbia – ME Therapeutics Holdings Inc. (“ME Therapeutics”), a preclinical biotechnology company focused on innovative immuno-oncology drugs, announced today that its subsidiary, ME Therapeutics Inc., will receive advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

This funding will support the research and development of ME Therapeutics’ mRNA therapeutic program, which targets myeloid cell biology for the treatment of cancer and inflammatory diseases.

“We’re thrilled to receive this continued support from NRC IRAP, which builds on previous advisory services and funding,” said Salim Dhanji, CEO of ME Therapeutics. “This will allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways.”

Dhanji emphasized the company’s belief in the potential of these therapies: “Our team passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who currently have limited options. We’re committed to bringing these potential new approaches to the clinic as soon as possible.”

ME Therapeutics has engineered proprietary mRNA sequences to encode proteins that can precisely modify the immune response in vivo. Their lead mRNA therapeutic candidate is designed to modulate immune cells within the tumor microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already shown encouraging anti-cancer activity in a mouse model of colorectal cancer. The company is also exploring modifications to its mRNA candidates to achieve tissue-specific mRNA expression, aiming for increased efficacy and safety.